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Abstract
Giant Cell Tumor of Bone (GCT) is an aggressive skeletal tumor characterized by local bone destruction, high recurrence
rates and metastatic potential. Previous work in our lab has shown that the neoplastic cell of GCT is a proliferating pre-
osteoblastic stromal cell in which the transcription factor Runx2 plays a role in regulating protein expression. One of the
proteins expressed by these cells is parathryroid hormone-related protein (PTHrP). The objectives of this study were to
determine the role played by PTHrP in GCT of bone with a focus on cell proliferation and apoptosis. Primary stromal cell
cultures from 5 patients with GCT of bone and one lung metastsis were used for cell-based experiments. Control cell lines
included a renal cell carcinoma (RCC) cell line and a human fetal osteoblast cell line. Cells were exposed to optimized
concentrations of a PTHrP neutralizing antibody and were analyzed with the use of cell proliferation and apoptosis assays
including mitochondrial dehydrogenase assays, crystal violet assays, APO-1 ELISAs, caspase activity assays, flow cytometry
and immunofluorescent immunohistochemistry. Neutralization of PTHrP in the cell environment inhibited cell proliferation
in a consistent manner and induced apoptosis in the GCT stromal cells, with the exception of those obtained from a lung
metastasis. Cell cycle progression was not significantly affected by PTHrP neutralization. These findings indicate that PTHrP
plays an autocrine/paracrine neoplastic role in GCT by allowing the proliferating stromal cells to evade apoptosis, possibly
through non-traditional caspase-independent pathways. Thus PTHrP neutralizing immunotherapy is an intriguing potential
therapeutic strategy for this tumor.
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Introduction
Giant Cell Tumor of Bone (GCT) is an aggressive and highly
osteolytic bone tumor that is characterized by local osteolysis,
regional pain and the predisposition to pathological fracture [1].
Current preferred treatment of GCT consists of limb sparing
surgery by the means of extended curettage with the addition of
local adjuvant therapies [2,3]. Albeit anatomy and function are
preserved with such an approach, local recurrence rates remain
high [4], thus emphasizing the importance of developing an
understanding of the biology of this tumor and subsequent
creation of more effective therapeutic options.
The cellular elements of GCT include both osteoclast-like giant
cells and proliferating osteoblast-like stromal cells [5]. Previous
work in our lab has shown that the osteoblastic transcription factor
Runx2 and AP-1 plays an important role in regulating protein
expression in the neoplastic cells stromal cells of GCT. [6,7,8,9].
Among these proteins, we have found that parathyroid hormone-
related protein (PTHrP) and its receptor are constitutively
expressed in this tumor [10]. In some pathways, such as the
Indian hedgehog (Ihh) pathway, Runx2 and PTHrP have been
shown to regulate each other in a reciprocal fashion [11,12,13].
PTHrP is present in many organs and tissues exerting its effects
through an autocrine/paracrine action [14]. PTHrP shares the
same N-terminal end as parathyroid hormone (PTH); therefore, it
can simulate most of the actions of PTH including increases in
bone resorption [15]. PTHrP was first identified as the tumor-
derived agent responsible for humoral hypercalcemia of malig-
nancy [16]. When produced in prodigious amounts by tumors,
PTHrP, by virtue of its ability to bind to and activate the G
protein–coupled PTH/PTHrP receptor, is the humoral factor
responsible for marked bone resorption and hypercalcemia
[17,18].
The majority of neoplastic tissues that metastasizes to bone
produce PTHrP, and PTHrP expression correlates with skeletal
localization of tumors [19]. Therefore, PTHrP is an intriguing
therapeutic target in the setting of malignancy, particularly in the
bone microenvironment. In fact, a recent study demonstrated the
anti-proliferative effect of PTHrP neutralizing antibody in
human renal cell carcinoma in vitro and in vivo [20]. The
objectives of this study were to determine if PTHrP plays a role
in cellular proliferation in GCT, and if so, to identify the
underlying mechanism of neoplastic proliferation provided by
PTHrP.
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Ethics statement
The use of all patient-derived material was approved by the
Hamilton Health Sciences and McMaster University Faculty of
Health Sciences Research Ethics Board (REB Project #: 05-302).
Written patient informed consent was obtained individually. The
Hamilton Health Sciences/McMaster University Research Ethics
Board operates in compliance with the ICH Good Clinical
Practice Guidelines and the Tri-Council Policy Statement: Ethical
Conduct for Research Involving Human and Division 5 Health
Canada Food and Drug Regulations.
GCT sample collection
The diagnosis of GCT of bone was established by biopsy prior
to surgical excision. Specimens were obtained at the time of
surgery from patients undergoing tumor resection and a bone
pathologist verified the diagnosis of GCT post-operatively. Tissue
samples from five cases of GCT of bone were used in this study
and all experiments were performed in triplicate or as otherwise
stated for all five patient specimens.
Primary cell lines and cultures
Primary cell cultures of GCT stromal tumor cells were isolated,
characterized and established from fresh GCT tissues as described
in our previous studies [7]. The specimens were freshly minced in
Dulbecco’s Modified Eagle Medium (D-MEM, Gibco, Burlington,
ON) producing a cell suspension with small fragments of tissue.
The resultant suspension was passed through a 20-gauge needle
prior to seeding in cell culture flasks with D-MEM supplemented
with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 U/
mL penicillin, and 100 mg/mL streptomycin (Gibco). The cell
suspension, together with macerated tissue, was cultured in 37uC
humidified air with 5% CO2. Culture medium was changed every
two to three days until ,80% confluence. Confluent cells (,80%)
were subcultured after dissociating with trypsin and ethylenedi-
aminetetraacetic acid (EDTA). Following several successive
passages, the mesenchymal stromal cells became the predominant
cell type whereas the multinucleated giant cells were eliminated
from the culture. Primary cultures of the proliferating homogenous
stromal tumor cell population obtained after the fifth or sixth
passage (without any hematopoietic markers) and up to the tenth
passage were used for experiments.
Human fetal osteoblast (hFOB) 1.19 cells (American Type
Culture Collection, ATCC#CRL-11372) and renal cell adeno-
carcinoma CRL1932 (Designation: 786-O, American Type
Culture Collection, ATCC#CRL-1932) were used as control cell
lines. hFOB cells were maintained in supplemented DMEM/F-12
medium at 33.5oC. CRL1932 cells were maintained in supple-
mented RPMI-1640. CRL1932 cells, as a positive control, are
known to produce PTHrP that is identical to peptides produced by
breast and lung tumors [21].
RNA purification and reverse transcription (RT)
Total RNA was isolated from GCT stromal cells using the
RNeasy mini kit (Qiagen, ON) as optimized in our lab. To ensure
complete removal of contaminating genomic DNA prior to first-
strand synthesis, RNase-free DNase I treatment was applied on the
RNeasy column during total RNA isolation. Single-stranded
complementary DNA (cDNA) was synthesized from 1.0 mgo f
total RNA using the SuperScripts III First-Strand Synthesis
System for RT-PCR (Invitrogen) and oligo(dT) 12–18 primer,
following the manufacturer’s instructions.
PCR and real-time polymerase chain reaction (PCR)
The expression of GAPDH and PTHrP was analyzed using
real-time RT-PCR. In brief, real-time PCR analysis was
performed on cDNA synthesized from GCT stromal cell total
RNA using the MiniOpticon Real-Time PCR Detection System
with the iQ SYBR Green Supermix (Bio-Rad Laboratories, ON)
according to the manufacturer’s instructions. Cycling consisted of
40 cycles of 15 s at 95uC, 30 s at 58uC, and 30 s at 72uC, operated
with the Opticon Monitor software v3.1. PCR experiments were
performed in triplicate and included negative no-template
controls. Primer pairs (Table 1) that spanned at least one
intron-exon boundary and produced amplicons in the range of
100-200 bp, were designed using the Real-time PCR Primer
Design software (VWR GenScript Corp., Piscatway, NJ), and
synthesized (Sigma-Aldrich, ON). In addition, a primer pair for
the housekeeping/reference gene GAPDH was also included. We
verified the amplicon specificity and sensitivity of all primer pairs
with PCR before applying to real-time PCR.
Relative quantification using real-time PCR
GAPDH was designated as the reference gene for relative
quantification, through which the expression of endogenous
mRNA from GCT stromal cells was normalized. Cycle threshold
(Ct) numbers were derived from the exponential phase of PCR
amplification. Relative changes in mRNA expression were
calculated using the comparative DDCT (crossing point) method.
Anti-PTHrP neutralization and PTHrP peptide rescue
Anti-PTHrP (1–34) neutralizing antiserum (T-4512, Bachem
Americas, Inc., CA) was used to neutralize secreted PTHrP. Cells
were seeded into 96 well plates at 16103 cells/well in medium
containing 10% FBS. After cell attachment (Day 0), cells were
transferred to serum-free medium treated either with 10 mg/ml
anti-PTHrP neutralizing antibody or 10 mg/ml IgG as a control.
This concentration was determined in our preliminary study on
the effect of toxicity and dosage response of the anti-PTHrP
neutralizing antibody in stromal cells [10]. A range of 1 nM to
10 mM of PTHrP peptide (1–34, Bachem Americas, Inc., CA) was
used to rescue cell death initiated by the neutralization of PTHrP.
As a positive control, the classic apoptotic agent, etoposide
(100 mM, Sigma Aldrich Canada Ltd., ON ) was used to
demonstrate an apoptotic positive result. On Day 2, the cell
culture medium was collected for the APO-1 apoptosis assay, and
cells were studied in proliferation assays and flow cytometry for
apoptosis and cell cycle analysis.
WST-1 cell proliferation measurement
Mitochondrial dehydrogenase activity, as an indicator of cell
number, was assessed by the mitochondrial-dependent reduction
of WST-1 to formazan. At indicated time-points over a 2-day time
course, 10 ml of the WST-1 premixed reagent (Roche Diagnostics,
Quebec) were added to each well on a 96 well plate, and the plates
were incubated at 37uC with 5% CO2 for 4 h, as recommended
by the manufacturer. Each well was initially seeded with
16104 cells. The plates were then placed on a shaker for 1 min,
and the absorbance was determined in the CytoFluor Multi-Well
Plate reader series 4000 (PerSeptive Biosystems) at 450 nm.
Crystal violet cell proliferation measurement
The cytotoxic effect of anti-PTHrP was assessed by measuring
the number of viable cells using crystal violet (CV). The CV
cytotoxicity test is based on the inability of dead cells to remain
adherent to cell culture plastic. As in the WST-1 cell proliferation
PTHrP in Bone Tumor Cells
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was removed from the 96 well plate and cells were washed two
times with cold PBS and then incubated with 200 ml of 70%
ethanol at 4uC for at least 30 min. After removing the ethanol,
cells were incubated with 100 ml of a 0.1% CV solution for 30 min
at room temperature. Excess CV was then removed by several
washes with water. Cell culture plates were dried overnight. CV
was dissolved in 33% acetic acid. The absorbance of the dissolved
dye, corresponding to the number of viable cells, was measured in
a microplate reader at 570 nm.
APO-1/Fas Enzyme-linked immunosorbent (ELISA) assay
The concentration of soluble APO-1/Fas antigen in cell culture
supernatants was measured in a quantitative ELISA (Invitrogen,
ON). The ELISA was performed following the manufacturer’s
protocol. The concentration of soluble APO-1 was calculated
using the absorbance reading at 450 nm, based on the results of a
standard dilution curve.
Caspase activity assay
Cells with various PTHrP treatments were seeded into a 96-well
plate as described above. The Apo-ONE Homogeneous Caspase-
3/7 assay (Promega Corp., WI) containing Z-DEVD-R110 was
performed to quantitate caspase activity levels according to the
manufacturer’s protocol. Cells were incubated for four hours at
ambient temperature prior to recording fluorescence (Ex =
485 nm; Em =530 nm).
Detection of apoptosis and cell cycle by flow cytometry
For apoptosis detection, cells were treated with anti-PTHrP
neutralizing antiserum as described above and harvested at day
2. Cells were trypsinized and washed with PBS twice and then
fixed with cold ethanol overnight. The extent of apoptosis was
quantified by using the Annexin V-EGFP Apoptosis Detection
Kit (GenScript USA Inc., NJ) as per the manufacturer’s
protocol. Most of the phosphatidylserines (PS) in the cell
membrane phospholipids translocate to the outer surface during
the early stages of apoptosis, and can be detected by staining
with an enhanced green fluorescent protein (EGFP) fused with
annexin V. In addition, propidium iodide (PI) is a nucleic dye,
which can only pass through the membranes of cells in middle
and late period of apoptosis and stain their nuclei red.
Detection of annexin V-EGFP binding at early apoptosis was
performed by flow cytometry (Ex =488 nm; Em =530 nm)
using an FITC signal detector and PI staining at later stages of
apoptosis by the phycoerythrin emission signal detector (Ex =
488 nm; Em =620 nm). Flow cytometry was performed on the
EPICS XL Cytometer (Beckman Coulter Canada, Inc., ON)
equipped with 3-color fluorescence air-cooled 488 nm argon
laser light source and detector range of 300 – 800 nm. The
EXPO32 ADC software provides both acquisition and analysis
for apoptosis.
For cell cycle analysis, the same treatment procedure, however
with PI alone, was administered to cells. Flow cytometry was then
performed using the PI detector and analyzed with a cell cycle
specific protocol in the EXPO32 ADC software. A total of 10000
events were acquired and the cells were properly gated for both
analyses.
Detection of apoptosis by confocal microscopy
The cells were cultured on round glass coverslips in a 60 mm
culture dish to about 70% confluency and subjected to anti-
PTHrP neutralizing antiserum as described above. The coverslips
were washed with PBS and fixed with cold ethanol overnight. The
cells were then labeled with Annexin V-EGFP, PI and 49,6-
diamidino-2-phenylindole (DAPI) for 30 min in binding buffer at
37uC. The coverslips were washed with PBS and mounted.
Stained nuclei and phophatidylserine were visualized and
photographed using a Leica DM-IRB laser scanning confocal
microscope (Leica Microsystem, Heidelberg, Germany). DAPI
(excitation at 360 nm and emission at 456 nm), PI (excitation at
488 nm and emission at 620 nm) and EGFP (excitation at 488 nm
and emission at 530 nm) were exited by the argon–krypton laser.
Apoptosis was characterized by the morphological changes,
namely, externalization of phosphatidylserine, cytoplasmic and
nuclear shrinkage, chromatin condensation, and formation of
apoptotic bodies.
Statistical analysis
GraphPad Prism software (GraphPad Software, Inc., USA) was
used for statistical analysis. All data are presented as mean 6
standard error of the mean (SEM), and are representative of
measurements that were performed on five different GCT patient
samples (n=5). To assess variations in real-time PCR gene
expression, analysis of variance (ANOVA) and the post-hoc
multiple comparison Tukey test (p,0.05) were applied. Measure-
ments were normalized to the negative control. Each experiment
was performed at least three times. P values ,0.05 were
considered to be statistically significant. The results of WST and
crystal violet tests were presented as a percentage of the control
value obtained in untreated cells.
Table 1. Human primer sequences special designed for real-time RT-PCR amplification.
Gene
Forward/
Reverse Primer sequence Accession #
Size of
product (bp)
Melting
temperature (6C)
PTHrP F 59 GGA GAC TGG TTC AGC AGT GG 39 NM_002820 133 57.0
R5 9 TTG TCA TGG AGG AGC TGA TG 39 (all 4 variants) 54.0
GAPDH F 59 CAT GAG AAG TAT GAC AAC AGC CT 39 NM_002046 113 55.0
R5 9 AGT CCT TCC ACG ATA CCA AAG T 39 56.0
Caspase-3 F 59 CAT GGA AGC GAA TCA ATG GAC T 39 NM_004346 139 56.0
R5 9 CTG TAC CAG ACC GAG ATG TCA 39 56.0
Caspase-9 F 59 AGG ATT TGG TGA TGT CGG TG 39 NM_001229 119 55.0
R5 9 CAC GGC AGA AGT TCA CAT TG 39 55.0
doi:10.1371/journal.pone.0019975.t001
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Expression of PTHrP in GCT stromal cells
To confirm the expression of PTHrP in GCT stromal cells,
PTHrP mRNA was quantitated for CRL1932, hFOB and stromal
cells of five GCT primary cell lines using real-time PCR. As
expected, the positive control CRL1932 expressed a relatively high
level of PTHrP (Fig. 1). Stromal cells of five GCT primary cell
lines on average expressed a relatively low level of PTHrP mRNA.
The expression of PTHrP protein by GCT stromal cells was
previously reported using both immunohistochemistry and western
blotting in our preliminary studies [10].
The Effect of anti-PTHrP neutralization on GCT stromal
cell morphology
To determine if blocking PTHrP activity would interfere with
GCT cell growth, we administered 10 mg/ml of anti-PTHrP
neutralizing antibody to cells. Both the CRL1932 cells and GCT
stromal cells exposed to the PTHrP neutralizing antibody
exhibited cytoplasmic shrinkage and formation of apoptotic bodies
(Figs. 2 C and F), similar to the apoptotic effects after treatment
with the classic apoptotic agent, etoposide (Figs. 2 B and E).
Control cells exposed to IgG appeared healthy (Figs. 2 A and D).
Neutralizing PTHrP protein expression decreases cell
proliferation
To measure the inhibitory effect of the anti-PTHrP neutralizing
antibody on GCT cell proliferation, we used two separate
approaches to assay cell viability. First, cell progression was
assessed using the WST-1 assay. The cell growth of positive
control CRL1932 cells was greatly reduced upon treatment with
anti-PTHrP antibody on day 2 (Fig. 3A). Likewise, hFOB
(Fig. 3B) and GCT stromal cells (Fig. 3C) decreased in cell
proliferation on day 2 when treated with anti-PTHrP antibody.
However, a subset of GCT stromal cells from a lung metastasis did
not show any significant depletion in cell proliferation under anti-
PTHrP treatment (Fig. 3D). Parallel experiments were conducted
in a similar fashion and evaluated with CV staining. All cells
demonstrated similar anti-PTHrP-induced growth reduction in
the CV assay as compared to that of the WST-1 assay (only data
from GCT stromal cells were shown in Fig. 3E). Cell progression
in stromal cells from a GCT lung metastasis was also confirmed to
be a subset within the CV assay in that cell proliferation was not
affected by PTHrP neutralization (data not shown).
The expression of of apoptotic markers
Soluble APO-1 (Fas/CD95) is a cell surface receptor that
mediates apoptosis when it reacts with Fas ligand (FasL). We
evaluated the effect of anti-PTHrP treatment on the levels of
soluble APO-1 protein released in the culture medium using an
APO-1 ELISA assay. As shown in Fig. 4A, CRL1932 cells
secreted a higher APO-1 protein level in cell culture medium when
treated with anti-PTHrP antibody. Similar increases in APO-1
levels were observed in the stromal cells from GCT. However,
stromal cells from the GCT lung metastasis subgroup did not show
any significant increases in APO-1 levels when exposed to PTHrP
neutralization (Fig. 4A).
After the initiation of the cell death process mediated by the
Fas/Apo-1 receptor, the activity of the caspase cascade is an
important consideration. We examined both the genetic expres-
sion of caspases and caspase protein activity levels. To confirm the
expression of caspase-3 and -9 mRNA in GCT stromal cells, both
genes were quantitated for all five PTHrP-neutralized GCT
primary cell lines using real time PCR. Unexpectedly, stromal cells
treated with PTHrP antiserum on average expressed a lower level
of caspase-3 and -9 mRNA (Fig. 4B). To further validate the
involvement of caspase cascade at the protein activity level, the
caspase-3/7 activity assay was performed. We confirmed that the
classic apoptotic caspase pathway was not actively involved in the
observed cell death when GCT cells were treated with PTHrP
neutralization (Fig. 4C). Positive caspase activation was confirmed
with etoposide, a DNA topoisomerase inhibitor.
Figure 1. Relative mRNA expression of PTHrP based on real-time RT-PCR. The average expression of PTHrP in five different GCT stromal
cells, CRL1932 and hFOB cells (controls). The DDCT method was used to calculate the real-time RT-PCR fold change using GAPDH mRNA for
normalization, and all changes in expression are relative to the control without any treatment. Triplicate independent real-time PCR experiments
were performed.
doi:10.1371/journal.pone.0019975.g001
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confocal microscopy
The externalization of PS is an early event in apoptosis which
could be determined using annexin V in flow cytometry. As a
control, PI, a cell-impermeant nuclear stain, was used. The
biparametric analysis of annexin V-EGFP versus PI of control cells
with IgG was portrayed as a cytogram (Fig. 5a, left column).
The majority of live cells were confined to the lower left quadrant
of each cytogram indicating only a background level of PI and
annexin V staining. Early apoptotic cells located in the lower right
quadrant are annexin V positive and PI negative; late apoptotic or
necrotic cells located in the upper right quadrant are PI positive
and annexin V positive. Etoposide was used to show the classic
apoptotic population distribution pattern on a cytogram (Sup-
plementary Figure S2).
Treatment with anti-PTHrP antiserum increased the external-
ization of PS indicating early apoptosis in CRL1932 and GCT
stromal cells as shown in Fig. 5a, right column. Stromal cells
from a GCT lung metastasis showed a very slight gain in both
annexin V and PI staining at the upper quadrants representing a
small but insignificant increase in late apoptosis and necrotic cell
death upon anti-PTHrP treatment. Figure 5b shows the average
early apoptotic index with both CRL1932 and stromal cells from
GCT undergoing early apoptosis in response to PTHrP neutral-
ization. However, stromal cells from a GCT lung metastasis did
not show a statistically significant increase in early apoptosis.
Identification of apoptotic cells by flow cytometry is generally
based on a single feature by the molecular marker of apoptosis.
Differential staining of cellular DNA and protein with DAPI,
annexin V and PI of the cells on slides gives a very good
morphological resolution of apoptosis and necrosis. The induction
of apoptosis was confirmed by immunofluorescence microscopy,
which showed chromatin condensation and apoptotic body
formation. The results of microscopy confirmed the increase in
early and late apoptotic cells in CRL1932 and GCT cells treated
with anti-PTHrP antibodies with the exception of GCT cells from
a lung metastasis (Fig. 5c).
Cell cycle analysis by flow cytometry
To identify the cell cycle phase regulation of PTHrP, serum-
starved cells were treated with or without anti-PTHrP antibody
and harvested for flow cytometric analysis using the PI staining
method. In contrast to the majority G0/G1 phase growth arrest in
IgG treated control CRL1932 cells, anti-PTHrP treatment shifted
the cell cycle progression to hypodiploid sub-G1 late apoptotic/
necrotic phase (Fig. 6A). Insignificant changes were observed in
the S and G2/M phases under anti-PTHrP treatment (Fig. 6B).
Likewise, GCT stromal cells demonstrated a shift from G0/G1 to
sub-G1 upon anti-PTHrP treatment in a lesser scale and also
showed insignificant changes in the S and G2/M phases under
anti-PTHrP treatment (Figs. 6A, B). Interestingly, no difference
in cell cycle phase distribution to the sub-G1 phase was noted after
anti-PTHrP treatment in stromal cells from a GCT lung
metastasis (Figs. 6A, B). Again, treatment with etoposide showed
a classic apoptotic population distribution pattern on the cell cycle
histogram with a mild disturbance within each cell cycle phase
(Supplementary Figure S1).
PTHrP neutralization reversed by PTHrP peptide
treatment
To further identify whether PTHrP neutralization would solely
contribute to the apoptotic phenomenon, we treated GCT stromal
cells with both PTHrP antibody and PTHrP peptide to determine
if ‘cell death rescue’ would occur. With incubation of both PTHrP
antibody and PTHrP peptide, the number of proliferating GCT
stromal cells increased significantly as compared to PTHrP
antibody treatment alone (Fig. 7 & Supplementary Figure
S3). PTHrP peptide treatment increased proliferation as expected.
Etoposide was a positive apoptotic indication.
Discussion
PTHrP plays various important roles at multiple stages during
bone formation through its effects on cell survival [22,23],
activation of growth factors, osteoblast cell proliferation [24],
and mature osteoblast function [25]. Our recent findings that
Runx2 and AP-1 is an important regulator in GCT stromal cells
[7,9] and that PTHrP is expressed by this tumor in vivo [10],
together with the fact that Runx2 and PTHrP regulate each other
in a reciprocal fashion through Ihh pathway [11,12,13], suggest
that PTHrP may be one of the possible upstream or downstream
effectors of Runx2. PTHrP has been shown to regulate tumor-
relevant genes and to play a role in tumorigenesis, modulation of
tumor progression and response to treatment in breast cancer and
Figure 2. Cell morphology in the presence or absence of anti-PTHrP treatment. Cell morphology of renal cell adenocarcinoma CRL1932 (A,
B, C) and GCT stromal cells (D, E, F) in the presence of IgG control (A, D), the apoptotic agent etoposide (B, E) and anti-PTHrP antiserum (C, F).
Representative pictures were taken with light microscope at magnification 6200. Black arrows indicate examples of cells undergoing apoptosis.
doi:10.1371/journal.pone.0019975.g002
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PTHrP in GCT stromal cells, anti-PTHrP neutralizing antiserum
was used to study the function of PTHrP in GCT cell proliferation
and cell cycle progression.
In this study, we report that GCT stromal cells express a
consistently modest level of PTHrP mRNA. The expression of
PTHrP and PTHrP-receptors has also been confirmed with
immunohistochemistry and western blotting in our preliminary
data [10]. Our findings align with others regarding the presence of
PTHrP in GCT cells [28,29]. In the current study, both stromal
cells of GCT and the classic PTHrP-secreting renal cell
adenocarcinoma CRL1932 showed signs of apoptosis with
cytoplasmic and nuclear shrinkage and formation of apoptotic
bodies upon anti-PTHrP treatment. The renal cell adenocarcino-
ma data found in this study confirm the results obtained by Talon
et al. in the same cell line [20].
Figure 3. The effect of PTHrP neutralization on cell proliferation. Cells were treated with anti-PTHrP antibodies and assayed for cell growth
using both WST-1 assay (A–D) and CV staining (E) over a two-day period. Total cell number was evaluated by measuring absorbance at 450 nm and
570 nm respectively. Cells assayed were A) CRL1932, B) hFOB, C & E) GCT stromal cells from primary bone and D) from a lung metastasis. Results are
means 6 SEM of triplicate independent experiments after normalized to the background control.
doi:10.1371/journal.pone.0019975.g003
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the WST-1 and CV cell proliferation assays. Blockade of PTHrP
ultimately halts the cell progression of stromal cells of GCT
primary bone tumors. Unexpectedly, a subset of GCT stromal
cells from a lung metastasis samples was identified based on its
insignificant response toward the anti-PTHrP neutralizing antise-
rum. This intriguing result may be related to the specific cell
microenvironment at the metastatic site and the distinct molecular
signature required for survival in that environment [30]. However,
this trend still needs to be validated with more lung metastatic
samples.
The apoptosis induced by anti-PTHrP neutralizing antibody in
GCT stromal cells was confirmed in this study with multiple
approaches. Induction of apoptosis and activation of caspases can
result from a variety of stimuli including growth factor withdrawal,
exposure to radiation or chemotherapeutic agents, or initiation of
the Fas/Apo-1 receptor-mediated cell death process. Increased
concentration of the soluble APO-1 cell surface receptor that
Figure 4. The effect of PTHrP on the expression of death markers. A) The effect of anti-PTHrP antibodies on the level of APO-1 concentration
in CRL1932 and GCT bone and lung metastasis stromal cells. Filtered and concentrated conditioned media from cell cultures treated with and without
anti-PTHrP antibodies were analyzed using the APO-1 ELISA kit as per optimization in our lab. Results of the ELISA assay in triplicate are shown by
error bars. The APO-1 concentration levels were normalized to the amount of total protein for each condition. *P,.05 is versus corresponding IgG
control values. Statistical comparison by analysis of variance with post hoc Tukey tests. B) Relative mRNA expression of caspase-3 and -9 based on
real-time RT-PCR in five different GCT stromal cells. The DDCT method was used to calculate the real-time RT-PCR fold change using GAPDH mRNA
for normalization, and all changes in expression are relative to the control without any treatment. Triplicate independent real-time PCR experiments
were performed. C) Caspase-3/7 activity assay was performed on GCT cells under various treatments in 96 well plate format. Average results of the
activity assay of five GCT cells in triplicate are shown by error bars.
doi:10.1371/journal.pone.0019975.g004
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of the direct mechanisms of apoptotic initiation in mammals is the
Fas-Fas ligand-mediated model through APO-1. Apoptosis
induced by PTHrP neutralization was equated by stimulation
with etoposide, a DNA topoisomerase inhibitor that leads to
caspase activation. Active caspases participate in a cascade of
cleavage events that disable key homeostatic and repair enzymes
and bring about systematic structural disassembly of dying cells.
However, mitochondrial-mediated caspase dependent apoptosis
was not observed in PTHrP antibody-treated GCT cells. PTHrP
Figure 6. The effect of PTHrP on cell cycle phase distribution in proliferating cells. CRL1932, GCT stromal cells from primary bone and a
lung metastasis were starvation synchronized and treated with either anti-PTHrP antiserum or IgG for two days. After fixing, cells were incubated with
PI and analyzed with flow cytometry. (A) Representative results from FACS analysis showed cell cycle distribution of proliferating CRL1932, GCT
stromal cells from primary bone and lung metastasis with either anti-PTHrP antiserum or IgG. (B) Percentage of cells in each cell cycle phase: Sub-G1,
G0/G1, S and G2/M. Values represent the means 6 SEM of triplicate experiments after normalized to the background control. *P,.05 is versus
corresponding IgG control values. Statistical comparison by analysis of variance with post hoc Tukey tests.
doi:10.1371/journal.pone.0019975.g006
Figure 5. Apoptosis induced by the anti-PTHrP antibody immunotherapy. A & B) CRL1932 and GCT stromal cells and GCT lung metastasis
were starvation synchronized and treated with either anti-PTHrP antiserum or IgG for two days. All cells were gated, and apoptosis was determined
by Annexin V-FITC and PI staining with flow cytometry. Numbers within quadrants represent percentages of live (lower left quadrant), early apoptotic
(lower right quadrant), and late apoptotic or necrotic (top left and right quadrant) cells. A) Representative results from FACS analysis showed
apoptotic/necrotic distribution of proliferating CRL1932, GCT stromal cells from primary bone and lung metastasis with either anti-PTHrP antiserum
or IgG. B) The average apoptotic index showing only the early apoptosis measurement for CRL1932 and GCT stromal cells from primary bone and a
lung metastasis. Values represent the means 6 SEM of triplicate independent experiments. C) Under the same treatment conditions, cells were
grown on cover slips and underwent fluorescent staining with DAPI, annexin V-EGFP and PI for morphological determination of apoptosis and
necrosis. Representative pictures were taken with corresponding filters using a fluorescent microscope.
doi:10.1371/journal.pone.0019975.g005
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PLoS ONE | www.plosone.org 9 May 2011 | Volume 6 | Issue 5 | e19975neutralization-induced cell death in GCT stromal cells may be a
result of either direct signal transduction via Fas/APO-1 pathway
or a caspase-independent apoptotic pathway that is mediated by
apoptosis-inducing factor.
Moreover, flow cytometry for apoptosis showed a shift to the
early apoptotic quadrant, as well as a shift to the subdiploid in cell
cycle analysis under anti-PTHrP treatment. In addition, photos
from light and immunofluorescent microscopy confirmed the
apoptotic changes in physiology and morphology of GCT stromal
cells when PTHrP was neutralized. All results led to the conclusion
that PTHrP neutralization stimulates apoptosis in the neoplastic
GCT stromal cells. Antagonistically, cell death induced by PTHrP
neutralization is reversed by PTHrP peptide treatment, indicating
the specificity of PTHrP action.
Apoptosis is the normal mechanism of cell turnover in
embryonic development, metamorphosis and hormone-dependent
atrophy of tissues [31]. Apoptosis exerts a homeostatic function in
maintaining a balance between cell replication and cell death.
Apoptotic cells are physiologically and morphologically different
from necrotic cells. Characteristics of cell morphology when
undergoing apoptosis included blebbing, loss of cell membrane
asymmetry and attachment, cell shrinkage, nuclear fragmentation,
chromatin condensation, and chromosomal DNA fragmentation
[32]. Most tumor cells are prone to have a higher resistance
against apoptosis and dysregulation of the cell as part of the
neoplastic evolution [33]. Results from this study suggest the
potential for anti-PTHrP treatment therapy in humans against
GCT from primary bone sites.
Increased expression of PTHrP is associated with the develop-
ment of bone metastasis in many tumors [19]. The question
remains as to whether PTHrP would be a viable therapeutic target
for primary bone tumors and bone metastases. Osteolysis caused
by human breast cancer metastases was shown to be blocked by
anti-PTHrP neutralizing antibodies [34]. Furthermore, a recent
study has shown a therapeutic effect of anti-PTHrP treatment with
zoledronic acid (a third-generation bisphosphonate) for bone
metastases of small cell lung cancer in severe combined
immunodeficient mice [35]. Similarly, immunization with anti-
PTH antibodies was effective in controlling hypercalcemia for
more than 72 months in patients with unresectable parathyroid
carcinoma in Phase III clinical trials [36,37].
Despite a significant number of studies that detailed the role of
PTHrP in tumorigenesis, such studies generated as many questions
as they answered [19]. Since the prognostic significance of PTHrP
expression on primary tumor cells is an unsettled issue, any clinical
utilities that manipulate PTHrP therapeutically need thoughtful
consideration and understanding of the underlying mechanisms
involved. Moreover, PTHrP might exert distinct effects on
different cell microenvironments [38]. Antibodies against PTH/
PTHrP, anti-RANKL therapy and bisphosphonates are at present
some of the promising therapies that could be introduced into
clinical trials; however, the underlying mechanisms of action
should first be explored and clearly documented [35,39,40].
In conclusion, we demonstrated for the first time and with
multiple assays that neutralization of PTHrP induces apoptosis in
stromal cells of GCT. The direct corollary dictates that PTHrP
serves to protect GCT stromal cells from apoptosis and therefore
contributes a neoplastic phenotype. This data constitutes a starting
point for clinical evaluation of anti-PTHrP strategies against
primary GCT of bone. To further investigate this possibility,
future studies exploring the mechanisms of apoptosis induced by
anti-PTHrP immunotherapy will be vital. In addition, the concept
that PTHrP serves to propagate proliferation in an autocrine
manner in GCT stromal cells is an intriguing model for further
investigation into this neoplastic phenomenon.
Supporting Information
Figure S1 The effect of PTHrP on cell cycle phase
distribution in proliferating cells. CRL1932 and GCT
stromal cells were starvation synchronized and treated with either
IgG vehicle, anti-PTHrP antiserum or the apoptotic agent
etoposide for two days. After fixing, cells were incubated with PI
and analyzed with flow cytometry. Representative results from
FACS analysis showed cell cycle distribution of proliferating
Figure 7. The reverse effect of PTHrP peptide treatment on cell proliferation. GCT stromal cells were treated with anti-PTHrP antibodies
and PTHrP peptide. Each condition was assayed for cell growth using CV staining over a two-day period. Total cell number was evaluated by
measuring absorbance at 570 nm. Results are means 6 SEM of triplicate independent experiments after normalized to the background control.
doi:10.1371/journal.pone.0019975.g007
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PLoS ONE | www.plosone.org 10 May 2011 | Volume 6 | Issue 5 | e19975CRL1932 and GCT stromal cells with either IgG vehicle, anti-
PTHrP antiserum or etoposide.
(TIF)
Figure S2 Apoptosis induced by the anti-PTHrP anti-
body immunotherapy. CRL1932 and GCT stromal cells were
starvation synchronized and treated with either IgG vehicle, anti-
PTHrP antiserum or the apoptotic agent etoposide for two days.
All cells were gated, and apoptosis was determined by Annexin V-
FITC and PI staining with flow cytometry. Numbers within
quadrants represent percentages of live (lower left quadrant), early
apoptotic (lower right quadrant), and late apoptotic or necrotic
(top left and right quadrant) cells. Representative results from
FACS analysis showed apoptotic/necrotic distribution of prolifer-
ating CRL1932 and GCT stromal cells with either IgG vehicle,
anti-PTHrP antiserum or etoposide.
(TIF)
Figure S3 Cell morphology in the presence of PTHrP
peptide, antibody or both. Cell morphology of GCT stromal
cells in the presence of IgG control, PTHrP peptide, anti-PTHrP
antiserum, and PTHrP peptide with antibody. Representative
pictures were taken with light microscope at magnification 6200.
Black arrows indicate examples of cells undergoing apoptosis.
(TIF)
Acknowledgments
We would like to thank Jian-Ping Lu, Toran Sanli, Eric Seidlitz and
Athanasios Paschos for helpful discussions.
Author Contributions
Conceived and designed the experiments: IWYM MG. Performed the
experiments: IWYM. Analyzed the data: IWYM. Contributed reagents/
materials/analysis tools: MG RET GS. Wrote the paper: IWYM.
Preliminary data: RWC. Proofread: MG GS RWC RET.
References
1. Turcotte RE (2006) Giant cell tumor of bone. Orthop Clin North Am 37: 35–51.
2. Balke M, Ahrens H, Streitbuerger A, Koehler G, Winkelmann W, et al. (2009)
Treatment options for recurrent giant cell tumors of bone. J Cancer Res Clin
Oncol 135: 149–158.
3. Balke M, Schremper L, Gebert C, Ahrens H, Streitbuerger A, et al. (2008) Giant
cell tumor of bone: treatment and outcome of 214 cases. J Cancer Res Clin
Oncol 134: 969–978.
4. Becker WT, Dohle J, Bernd L, Braun A, Cserhati M, et al. (2008) Local
recurrence of giant cell tumor of bone after intralesional treatment with and
without adjuvant therapy. J Bone Joint Surg Am 90: 1060–1067.
5. Ghert M, Simunovic N, Cowan RW, Colterjohn N, Singh G (2007) Properties of
the stromal cell in giant cell tumor of bone. Clin Orthop Relat Res 459: 8–
13.
6. Cowan RW, Mak IW, Colterjohn N, Singh G, Ghert M (2009) Collagenase
expression and activity in the stromal cells from giant cell tumour of bone. Bone
44: 865–871.
7. Mak IW, Cowan RW, Popovic S, Colterjohn N, Singh G, et al. (2009)
Upregulation of MMP-13 via Runx2 in the stromal cell of Giant Cell Tumor of
bone. Bone 45: 377–386.
8. Mak IW, Seidlitz EP, Cowan RW, Turcotte RE, Popovic S, et al. (2010)
Evidence for the role of matrix metalloproteinase-13 in bone resorption by giant
cell tumor of bone. Hum Pathol 41: 1320–1329.
9. Mak IW, Turcotte RE, Popovic S, Singh G, Ghert M (2011) AP-1 as a
Regulator of MMP-13 in the Stromal Cell of Giant Cell Tumor of Bone.
Biochem Res Int 2011: 164197. pp 164197.
10. Cowan R, Singh G, Ghert M. The role of parathyroid hormone-related protein
in giant cell tumour of bone. 2010 SEP 22–25, 2010 Sheffield, ENGLAND.
Bone S48.
11. Iwamoto M, Kitagaki J, Tamamura Y, Gentili C, Koyama E, et al. (2003)
Runx2 expression and action in chondrocytes are regulated by retinoid signaling
and parathyroid hormone-related peptide (PTHrP). Osteoarthritis Cartilage 11:
6–15.
12. Ueta C, Iwamoto M, Kanatani N, Yoshida C, Liu Y, et al. (2001) Skeletal
malformations caused by overexpression of Cbfa1 or its dominant negative form
in chondrocytes. J Cell Biol 153: 87–100.
13. Vortkamp A, Lee K, Lanske B, Segre GV, Kronenberg HM, et al. (1996)
Regulation of rate of cartilage differentiation by Indian hedgehog and PTH-
related protein. Science 273: 613–622.
14. Burtis WJ (1992) Parathyroid hormone-related protein: structure, function, and
measurement. Clin Chem 38: 2171–2183.
15. Datta NS, Abou-Samra AB (2009) PTH and PTHrP signaling in osteoblasts.
Cell Signal 21: 1245–1254.
16. Philbrick WM, Wysolmerski JJ, Galbraith S, Holt E, Orloff JJ, et al. (1996)
Defining the roles of parathyroid hormone-related protein in normal physiology.
Physiol Rev 76: 127–173.
17. Suva LJ, Winslow GA, Wettenhall RE, Hammonds RG, Moseley JM, et al.
(1987) A parathyroid hormone-related protein implicated in malignant
hypercalcemia: cloning and expression. Science 237: 893–896.
18. Juppner H, Abou-Samra AB, Freeman M, Kong XF, Schipani E, et al. (1991) A
G protein-linked receptor for parathyroid hormone and parathyroid hormone-
related peptide. Science 254: 1024–1026.
19. Nishihara M, Kanematsu T, Taguchi T, Razzaque MS (2007) PTHrP and
tumorigenesis: is there a role in prognosis? Ann N Y Acad Sci 1117: 385–392.
20. Talon I, Lindner V, Sourbier C, Schordan E, Rothhut S, et al. (2006) Antitumor
effect of parathyroid hormone-related protein neutralizing antibody in human
renal cell carcinoma in vitro and in vivo. Carcinogenesis 27: 73–83.
21. Thiede MA, Strewler GJ, Nissenson RA, Rosenblatt M, Rodan GA (1988)
Human renal carcinoma expresses two messages encoding a parathyroid
hormone-like peptide: evidence for the alternative splicing of a single-copy gene.
Proc Natl Acad Sci U S A 85: 4605–4609.
22. Manolagas SC (2000) Birth and death of bone cells: basic regulatory mechanisms
and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev
21: 115–137.
23. Chen HL, Demiralp B, Schneider A, Koh AJ, Silve C, et al. (2002) Parathyroid
hormone and parathyroid hormone-related protein exert both pro- and anti-
apoptotic effects in mesenchymal cells. J Biol Chem 277: 19374–19381.
24. Nishida S, Yamaguchi A, Tanizawa T, Endo N, Mashiba T, et al. (1994)
Increased bone formation by intermittent parathyroid hormone administration
is due to the stimulation of proliferation and differentiation of osteoprogenitor
cells in bone marrow. Bone 15: 717–723.
25. Qin L, Raggatt LJ, Partridge NC (2004) Parathyroid hormone: a double-edged
sword for bone metabolism. Trends Endocrinol Metab 15: 60–65.
26. Luparello C, Romanotto R, Tipa A, Sirchia R, Olmo N, et al. (2001) Midregion
parathyroid hormone-related protein inhibits growth and invasion in vitro and
tumorigenesis in vivo of human breast cancer cells. J Bone Miner Res 16:
2173–2181.
27. Liao J, McCauley LK (2006) Skeletal metastasis: Established and emerging roles
of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev 25:
559–571.
28. Nakashima M, Nakayama T, Ohtsuru A, Fukada E, Niino D, et al. (2003)
Expression of parathyroid hormone (PTH)-related peptide (PthrP) and PTH/
PTHrP receptor in osteoclast-like giant cells. Pathol Res Pract 199: 85–92.
29. Kartsogiannis V, Udagawa N, Ng KW, Martin TJ, Moseley JM, et al. (1998)
Localization of parathyroid hormone-related protein in osteoclasts by in situ
hybridization and immunohistochemistry. Bone 22: 189–194.
30. Wikman H, Vessella R, Pantel K (2008) Cancer micrometastasis and tumour
dormancy. APMIS 116: 754–770.
31. Blank M, Shiloh Y (2007) Programs for cell death: apoptosis is only one way to
go. Cell Cycle 6: 686–695.
32. Kanduc D, Mittelman A, Serpico R, Sinigaglia E, Sinha AA, et al. (2002) Cell
death: apoptosis versus necrosis (review). Int J Oncol 21: 165–170.
33. Klein G (2004) Cancer, apoptosis, and nonimmune surveillance. Cell Death
Differ 11: 13–17.
34. Guise TA, Kozlow WM, Heras-Herzig A, Padalecki SS, Yin JJ, et al. (2005)
Molecular mechanisms of breast cancer metastases to bone. Clin Breast Cancer
5 Suppl: S46–53.
35. Yamada T, Muguruma H, Yano S, Ikuta K, Ogino H, et al. (2009)
Intensification therapy with anti-parathyroid hormone-related protein antibody
plus zoledronic acid for bone metastases of small cell lung cancer cells in severe
combined immunodeficient mice. Mol Cancer Ther 8: 119–126.
36. Bradwell AR, Harvey TC (1999) Control of hypercalcaemia of parathyroid
carcinoma by immunisation. Lancet 353: 370–373.
37. Betea D, Bradwell AR, Harvey TC, Mead GP, Schmidt-Gayk H, et al. (2004)
Hormonal and biochemical normalization and tumor shrinkage induced by anti-
parathyroid hormone immunotherapy in a patient with metastatic parathyroid
carcinoma. J Clin Endocrinol Metab 89: 3413–3420.
38. Henderson MA, Danks JA, Slavin JL, Byrnes GB, Choong PF, et al. (2006)
Parathyroid hormone-related protein localization in breast cancers predict
improved prognosis. Cancer Res 66: 2250–2256.
39. Thomas DM, Skubitz KM (2009) Giant cell tumour of bone. Curr Opin Oncol
21: 338–344.
40. Tse LF, Wong KC, Kumta SM, Huang L, Chow TC, et al. (2008)
Bisphosphonates reduce local recurrence in extremity giant cell tumor of bone:
a case-control study. Bone 42: 68–73.
PTHrP in Bone Tumor Cells
PLoS ONE | www.plosone.org 11 May 2011 | Volume 6 | Issue 5 | e19975